reason report
refocus back consum healthcar root pt
primarili gener conjunct decis separ
gener busi would allow focu close
core chc busi disagre strategi
enhanc focu chc believ extend
topic gener busi attract one given barrier
entri industri margin profil howev unclear
us separ busi immedi unlock valu
enhanc growth trajectori segment independ
look visibl initi identifi
strateg review confer call septemb
updat model reflect lower guidanc reduc
ep
reiter mp rate lower pt
chang model lower rx sale
model lower revenu outer year also lower
oper margin much also
lower chci revenu gm increas
year assum mostli re-invest
busi continu see oper margin
rang within year overal amount top-lin hit
total compani revenu impact
lower pt
decis separ rx busi base bottom-up
review conclud rx busi differ
natur consum busi justifi keep togeth
explain rx segment requir focus
portfolio manag servic limit number distributor
consum busi distinct entail creat solut
rang retail consum leverag complex suppli chain
manag believ divestitur creat sharehold valu
free compani clash busi model build
synergi elsewher better posit execut growth
initi regard rx manag also suggest
segment need lean oper drive quick decis make
first-to-file/first-to-market ftf/ftm expect
manag disclos develop separ
process specif action select
ev/ebitda multipl
net debt total capit
compani inform leerink partner llc research
revenu
pleas refer page import disclosur price chart analyst certif
manag believ get good price rx segment
due differenti focu extend topic manag
believ rx segment attract busi due
differenti product portfolio excel cash flow robust
oper margin manag emphas strong oper
margin given durabl despit continu price
eros rel new product launch manag
expect overhead overhang believ potenti dis-synergi
separ rx busi manag
within consum explor organ in-
organ opportun drive growth consum segment
manag declin comment specif initi drive growth
said select strategi design around compani
core capabl among possibl describ manag
organic/inorgan opportun respect rx over-the-counter switch
capit alloc drive oper profit oper effici
manag look total rx-to-otc switch would
fit compani capabl custom identifi
number potenti switch recent announc nasonex deal
first look addit color avenu growth
manag host call septemb
addit takeaway chci manag continu drive strong
oper margin reiter focu reinvest profit
busi still look reach high teen oper margin
year rx manag remain commit bring gx proair
market provid addit detail
fda need see approv contribut lower sale
outlook segment delay number author gener
ag partnership expect launch restor
suppli scopolamin longer expect occur
rate market perform believ consum healthcar america chca like
continu grow low-singl digit consum healthcar chci also
grow low-singl digit growth potenti manag initi take time
play howev unclear decis separ rx busi immedi
unlock valu enhanc growth consum healthcar segment
current still limit visibl medium-/long-term growth trajectori busi
drug producttop indicationev detailsd rangeimpact igh ow consum busi updatesept gellaunch gener androgel mdiasthma/copdpotenti approv rx perrigo compani plc
figur chang model
lp estim note number except ep margin
figur chang model continu
lp estim note number except ep margin
consum healthcar americasnet oper marginconsum healthcar internationalnet oper marginrx pharmaceuticalsnet oper margintot adjust net dsg oper effect tax share outstandingoper new product perrigo compani plc
note revenu
changevalu changevarianceconsensusactu vs conssegmentschc dilut non-gaap adjustmentstot one-tim net perrigo compani plc
note revenu
use ebitda appli weight averag ev/ebitda multipl
arriv pt
limit rx-to-otc switch opportun and/or delay new rx over-the-counter product launch
could result share trade lower expect initi drive busi may
success anticip lead share perform better expect
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
long term growth
gsk product yokeb
number except per share data
gx bodi oil dermat
gx estrac estradiol vagin cream expect launch
gx finacea foam azela acid progress month stay expir juli
gx soolantra cream ivermectin rosacea ftf case progress
gx prolensa bromfenac ophthalm solut confidenti settlement assum compound patent tent approv
number except per share data
number except per share data
number except per share data
number except per share data
number except per share data
tysabri royalti stream fair valu
payrol relat tax
number except per share data
adjust reconcil ni net cash oper
tysabri toyalti stream chang fair valu
loss extinguish debt
impair equiti invest net
decreas increas work capit
proce royalti right
acquisit businesses/asset net cash acquir
proceed sale busi
settlement acquisition-rel foreign currenc deriv
purchas properti plant equip capital-expenditure
net invest
borrow repay revolv credit/oth net
premium earli debt retir
issuanc ordinari share
net financ
effect exchang rate chang cash/ cash equival
net chang equival
